Recent Quotes (30 days)

You have no recent quotes
chg | %

Neptune Technologies & Bioressources-Ord  

(Public, NASDAQ:NEPT)   Watch this stock  
Find more results for NEPT
2.73
0.00 (0.00%)
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.62 - 5.14
Open     -
Vol / Avg. 0.00/282,143.00
Mkt cap 163.98M
P/E     -
Div/yield     -
EPS -0.30
Shares     -
Beta 2.46
Inst. own     -
Jun 27, 2013
Neptune Technologies & Bioressources Inc Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
May 23, 2013
Q4 2012 Neptune Technologies & Bioressources Inc Earnings Conference Call
May 23, 2013
Q4 2012 Neptune Technologies & Bioressources Inc Earnings Release
Mar 19, 2013
Neptune Technologies & Bioressources Inc at Roth Conference
More events from DailyFinance »    

Address

Suite 200 225 Promenade du Centropolis
LAVAL, QC H7T 0B3
Canada
+1-450-6872262 (Phone)
+1-450-6872272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Neptune Technologies & Bioressources Inc. is a biotechnology company engaged in the research and development of extraction technologies. The Company�s main focuses is to identify marine biomasses pure from toxins, abundant and underexploited; to research, develop and commercialize technology for the extraction and stabilization of potent marine biological therapeutic agents, and to research and develop the safety and therapeutic efficacy of compounds for prevalent atherosclerotic conditions. It operates in three segments: Neptune, Acasti Pharma Inc. and NeuroBioPharm Inc. Its Neptune segment is engaged in the manufacturing and commercialization of nutraceutical products. Its Acasti Pharma segment is involved in the development and commercialization of pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharma segment is involved in the development of commercialization of pharmaceutical products for neurological diseases.

Officers and directors

Ronald Denis Independent Chairman of the Board
Bio & Compensation  - Reuters
Henri Harland President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Andre Godin Chief Financial Officer
Bio & Compensation  - Reuters
Michel Chartrand Chief Operating Officer, Director
Bio & Compensation  - Reuters
Fotini Sampalis M.D., Ph.D. Chief Global Strategy Officer
Bio & Compensation  - Reuters
Harlan W. Waksal M.D. Director
Age: 59
Bio & Compensation  - Reuters
Jean-Claude Debard Independent Director
Bio & Compensation  - Reuters
Daniel Perry Independent Director
Bio & Compensation  - Reuters